The treatment of advanced gastric cancer:: current strategies and future perspectives

被引：72

作者：

Cervantes, A. ^{[1
]}

Rosello, S. ^{[1
]}

Roda, D. ^{[1
]}

Rodriguez-Braun, E. ^{[1
]}

机构：

[1] Univ Valencia, Hosp Clin Univ, Dept Hematol & Med Oncol, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

10.1093/annonc/mdn321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：103 / 107

页数：5

相关论文

共 49 条

[1] Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group [J].

Ajani, Jaffer A. ;

Moiseyenko, Vladimir M. ;

Tjulandin, Sergei ;

Majlis, Alejandro ;

Constenla, Manuel ;

Boni, Corrado ;

Rodrigues, Adriano ;

Fodor, Miguel ;

Chao, Yee ;

Voznyi, Edouard ;

Awad, Lucile ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3210-3216

[2] Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 study group [J].

Ajani, Jaffer A. ;

Moiseyenko, Vladimir M. ;

Tjulandin, Sergei ;

Majlis, Alejandro ;

Constenla, Manuel ;

Boni, Corrado ;

Rodrigues, Adriano ;

Fodor, Miguel ;

Chao, Yee ;

Voznyi, Edouard ;

Marabotti, Cindy ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3205-3209

[3]

[Anonymous], ANN ONCOLOGY S5

[4]

[Anonymous], J NATL CANC I

[5] Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma [J].

Assersohn, L ;

Brown, G ;

Cunningham, D ;

Ward, C ;

Oates, J ;

Waters, JS ;

Hill, ME ;

Norman, AR .

ANNALS OF ONCOLOGY, 2004, 15 (01) :64-69

[6]

Barone C, 1998, CANCER-AM CANCER SOC, V82, P1460, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1460::AID-CNCR5>3.0.CO

[7]

2-D

[8] Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803 [J].

Bouche, O ;

Raoul, JL ;

Bonnetain, F ;

Giovannini, M ;

Etienne, PL ;

Lledo, G ;

Arsène, D ;

Paitel, JF ;

Guérin-Meyer, V ;

Mitry, E ;

Buecher, B ;

Kaminsky, MC ;

Seitz, JF ;

Rougier, P ;

Bedenne, L ;

Milan, C .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4319-4328

[9] High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) [J].

Cascinu, S ;

Scartozzi, M ;

Labianca, R ;

Catalano, V ;

Silva, RR ;

Barni, S ;

Zaniboni, A ;

D'Angelo, A ;

Salvagni, S ;

Martignoni, G ;

Beretta, GD ;

Graziano, F ;

Berardi, R ;

Franciosi, V .

BRITISH JOURNAL OF CANCER, 2004, 90 (08) :1521-1525

[10] Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].

Chou, I ;

Norman, AR ;

Cunningham, D ;

Waters, JS ;

Oates, J ;

Ross, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2395-2403

← 1 2 3 4 5 →